Oculis Holding Yönetim

Yönetim kriter kontrolleri 0/4

Oculis Holding CEO'su Riad Sherif, Dec2017 tarihinde atandı, in görev süresi 6.92 yıldır. şirketin hisselerinin 2.09% doğrudan sahiptir ve bu hisselerin değeri € 12.89M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.8 yıl ve 2 yıldır.

Anahtar bilgiler

Riad Sherif

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	6.9yrs
CEO sahipliği	2.1%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	2yrs

Son yönetim güncellemeleri

Recent updates

CEO

Riad Sherif (56 yo)

6.9yrs

Görev süresi

Dr. Riad Sherif, MD, MBA, has been the Chief Executive Officer and Director of Oculis Holding AG (formerly known as Oculis SA) since December 2017. He is Chief Executive Officer and Director of Oculis ehf....

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Riad Sherif	CEO & Director	6.9yrs	Veri yok	2.09% € 12.9m
Sylvia Cheung	Chief Financial Officer	4.2yrs	Veri yok	0.16% € 980.1k
Gudrun Bachmann	Chief Technology Officer	less than a year	Veri yok	Veri yok
Ramin Tadayoni	Chief Scientific Officer	less than a year	Veri yok	Veri yok
Daniel Char	Chief Legal Officer	less than a year	Veri yok	Veri yok
Virginia Dean	Chief Human Resources Officer	less than a year	Veri yok	Veri yok
Páll Jóhannesson	Chief Business Officer	4.2yrs	Veri yok	0.59% € 3.7m
Rebecca Weil	Chief Commercial Officer	1.2yrs	Veri yok	Veri yok
Snehal Shah	President of Research & Development	less than a year	Veri yok	Veri yok
Sharon Klier	Chief Development Officer	less than a year	Veri yok	Veri yok
Isabelle de Chambrier	Senior Vice President of Quality	1.2yrs	Veri yok	Veri yok

0.8yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: CR5 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Riad Sherif	CEO & Director	6.9yrs	Veri yok	2.09% € 12.9m
Eric Donnenfeld	Chair of Cornea Scientific Advisory Board	no data	Veri yok	Veri yok
Anthony Rosenberg	Independent Chairman	6.6yrs	Veri yok	0.23% € 1.4m
Christophe Baudouin	Member of Scientific Advisory Board	2yrs	Veri yok	Veri yok
Peter Kaiser	Member of Scientific Advisory Board	2yrs	Veri yok	Veri yok
Lionel Carnot	Independent Director	6.9yrs	Veri yok	Veri yok
Christina Ackermann	Independent Director	1.7yrs	Veri yok	0.028% € 171.9k
Quan Dong Nguyen	Member of Scientific Advisory Board	2yrs	Veri yok	Veri yok
Robert Warner	Director	less than a year	Veri yok	Veri yok
Arshad Khanani	Chair of Retina Scientific Advisory Board & Director	2yrs	Veri yok	Veri yok
Anat Loewenstein	Member of Scientific Advisory Board	2yrs	Veri yok	Veri yok
Pablo Villoslada	Member of Scientific Advisory Board	2yrs	Veri yok	Veri yok

2.0yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CR5 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Oculis Holding Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Oculis Holding AG Announces Appointment of Daniel S. Char as Chief Legal Officer

Oculis Holding AG Appoints Sharon Klier as Chief Development Officer

Oculis Holding AG Announces Board and Committee Appointments

Oculis Holding AG, Annual General Meeting, May 29, 2024

Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development

Oculis Holding AG Appoints Rebecca Weil as Chief Commercial Officer

Recent updates

Oculis Holding AG Announces Appointment of Daniel S. Char as Chief Legal Officer

Second quarter 2024 earnings released: CHF0.51 loss per share (vs CHF0.38 loss in 2Q 2023)

Oculis Holding AG Appoints Sharon Klier as Chief Development Officer

Oculis Holding AG to Report Q2, 2024 Results on Aug 14, 2024

New major risk - Revenue and earnings growth

Oculis Holding AG Announces Positive Topline Results of Phase 2b RelieF Trial with Licaminlimab Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

Oculis Holding AG Announces Board and Committee Appointments

First quarter 2024 earnings released: CHF0.44 loss per share (vs CHF1.27 loss in 1Q 2023)

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $100 million.

Oculis Holding AG, Annual General Meeting, May 29, 2024

Oculis Holding AG has completed a Follow-on Equity Offering in the amount of $58.75 million.

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $58.75 million.

Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development

Oculis Holding Ag Announces Positive Results from Phase 3 Optimize-1 Trial of Once Daily Ocs-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

Full year 2023 earnings released: CHF2.97 loss per share (vs CHF12.95 loss in FY 2022)

New major risk - Revenue and earnings growth

Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

Oculis Holding AG Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema

Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNF ALPHA> Licaminlimab (OCS-02) in Dry Eye Disease

Third quarter 2023 earnings released: CHF0.48 loss per share (vs CHF3.29 loss in 3Q 2022)

Oculis Holding AG announced that it has received $71.18891 million in funding from a group of investors

Oculis Holding AG Announces Positive Phase 3 Stage 1 Diamond Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress

Oculis Holding to Present Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 Diamond Trial Results for Diabetic Macular Edema

New major risk - Revenue and earnings growth

Oculis Holding AG Appoints Rebecca Weil as Chief Commercial Officer

Second quarter 2023 earnings released: CHF0.38 loss per share (vs CHF3.29 loss in 2Q 2022)

Oculis Holding Ag Announces Positive Top Line Results from Its Phase 3 Optimize Trial with Ocs-01 Eye Drops

High number of new directors

Oculis Holding AG to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases

High number of new directors

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş